Movement Alert｜WUXI BIO Falls 3.06% in Regular Trading, UBS Downgrade to Neutral Weighs on Sentiment

Market Focus10-26

On October 26, WUXI BIO fell 3.06% in Regular Trading, trading at HK$44.48, with turnover of HK$439 million.

The clearest catalyst was a recent broker action: UBS downgraded the company to Neutral and set a target price of RMB27, which has pressured near-term sentiment.

Earlier disclosures had shown interim revenue of RMB11.787 billion and adjusted net profit of RMB3.937 billion, while its Wuxi Mashan site also passed an unannounced FDA GMP inspection without major or critical findings. Even so, the rating downgrade appears to have outweighed those positives in the current session, with peer names including WUXI APPTEC and WUXI XDC also weaker.

The company provides end-to-end solutions for biologics discovery, development and manufacturing, and also operates an XDC business serving ADCs and other bioconjugates.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment